FDA Finalizes Regulatory Review Period for Blujepa
February 13, 2026
February 13, 2026
WASHINGTON, Feb. 13 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced that it has determined the regulatory review period for the human drug product Blujepa. This determination follows an application for patent term extension submitted by Glaxo Group Ltd., London, England, to the U.S. Department of Commerce Patent and Trademark Office.
Blujepa, known chemically as gepotidacin mesylate, is an antibacterial drug approved for treating un . . .
Blujepa, known chemically as gepotidacin mesylate, is an antibacterial drug approved for treating un . . .